Vertex PharmaceuticalsWBO:VRTX +0.52%91 Days Inventory is 398.64 as of Mar. 2026, which is 214% above its 10-year median of 126.80. GuruFocus rates WBO:VRTX with a GF Score™ of 91/100 and a GF Value™ of €440.30 (Fairly Valued). The stock has 4 warning signs investors should review. Among 638 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 72.57% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Vertex Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.23.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vertex Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.57.
Vertex Pharmaceuticals (WBO:VRTX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Vertex Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Vertex Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Vertex Pharmaceuticals Days Inventory Related Terms
Vertex Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VRTX vs REGN, ALNY, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (WBO:VRTX) has a Days Inventory of 398.64 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vertex Pharmaceuticals and its competitors. This is 214% above median its historical median of 126.80. Over the past decade, Vertex Pharmaceuticals' Days Inventory has ranged from 97.23 to 344.76. According to the industry distribution chart, Vertex Pharmaceuticals ranks #463 out of 638 companies in the Biotechnology industry, placing it in the top 72.6%.
Is Vertex Pharmaceuticals' Days Inventory too high?
Vertex Pharmaceuticals' current Days Inventory of 398.64 is 214% above median its 10-year median of 126.80. Over the past 10 years, this metric has ranged from a low of 97.23 to a high of 344.76. The Biotechnology industry median Days Inventory is 183.88. Vertex Pharmaceuticals' value of 398.64 is 116.8% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #463 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Days Inventory compare to REGN and ALNY?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #463 out of 638 companies for Days Inventory. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.88. Vertex Pharmaceuticals' value of 398.64 is 116.8% above this benchmark. Historically, Vertex Pharmaceuticals' own Days Inventory has ranged from 97.23 to 344.76 over the past decade. While the company's 10-year median is 126.80 vs. the industry median of 183.88, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Days Inventory of 398.64 is 116.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Days Inventory is 398.64, which is 214% above median its own 10-year median of 126.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.30, compared to a current price of €435.40 — trading 1.1% below its estimated fair value. The current Days Inventory is 398.64, which is 214% above median its 10-year median of 126.80 and 116.8% above the Biotechnology industry median of 183.88. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Days Inventory is 398.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €435.40 is trading 1.1% below its estimated GF Value™ of €440.30.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for WBO:VRTX:
Days Inventory: 398.64 (214% above median its 10-year median of 126.80)
GF Value™: €440.30 vs. price of €435.40 (1.1% below fair value)
Industry Position: 116.8% above the Biotechnology median (#463 of 638)
No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for WBO:VRTX
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VRTX has been successfully added to your 
